Clinical Trials Logo

Clinical Trial Summary

The purpose of this research is to determine whether bladder cancer monitoring can be improved by replacing some cystoscopy procedures with urine testing. Specifically, this study examines whether there are any differences in urinary symptoms, discomfort, number of invasive procedures, anxiety, complications, cancer recurrence or cancer progression when some cystoscopy procedures are replaced with urine testing.


Clinical Trial Description

This is a multi-site randomized phase 2 trial including 240 patients with early-stage bladder cancer, in which patients will be randomized 1:1:1 to programmatic surveillance with the Xpert bladder cancer urine test, the Bladder EpiCheck urine test, or frequent cystoscopy. The primary outcome will be urinary quality of life measured 1 to 3 days after surveillance. This study will have three groups, also called "arms": (1) Frequent Cystoscopy Arm, (2) Xpert Urine Test Arm, and (3) Epicheck Urine Test Arm. The aim of Frequent Cystoscopy is to detect any cancer that might have come back within the bladder by frequently inspecting the bladder. Those in the cystoscopy arm will have a cystoscopy procedure at specified time points for two years. The goal of the Xpert Urine Test arm is to detect any cancer that might have come back within the bladder, while decreasing the number of invasive cystoscopy procedures. Those in the Xpert arm will have a Xpert urine test and a check-up with a medical doctor at 6 months and 18 months, and have a cystoscopy procedure at 12 months and 24 months. The aim of the EpiCheck Urine Test arm is to detect any cancer that might have come back within the bladder, while decreasing the number of invasive cystoscopy procedures. Those in the EpiCheck Urine Test arm will have an Epicheck urine test and a check-up with a medical doctor at 6 months and 18 months and will have a cystoscopy procedure at 12 months and 24 months. The study performance period is 24 months. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05796375
Study type Interventional
Source White River Junction Veterans Affairs Medical Center
Contact Florian R Schroeck, MD, MS
Phone 802-295-9363
Email florian.schroeck@va.gov
Status Recruiting
Phase N/A
Start date November 17, 2023
Completion date May 30, 2029

See also
  Status Clinical Trial Phase
Recruiting NCT05483868 - A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer Phase 1
Not yet recruiting NCT05547516 - Blue Laser -5ala Photodynamic Therapy (PDT) in High-Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients N/A
Not yet recruiting NCT05580354 - Safety and Efficacy of BCG Combined With Tislelizumab for BCG-untreated Patients With High-risk Non-muscle Invasive Bladder Cancer Phase 4
Recruiting NCT05519241 - A Phase I Intravesical PPM Therapy for NMIBC Phase 1
Not yet recruiting NCT05002556 - AFU Registry of the Therapeutic Management and Follow-up of Non-Muscle-Invasive Bladder Cancer
Recruiting NCT05544552 - Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations Phase 1/Phase 2
Active, not recruiting NCT03528694 - Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer Phase 3
Recruiting NCT05790850 - Pre-Habilitation With Mindfulness and Exercise for Patients Undergoing Radical Cystectomy (PRIMER Trial) N/A
Completed NCT03664258 - A Multi-National Study In Bladder Cancer Patients to Detect Recurrences After TURB (Trans-urethral Resection of the Bladder) Earlier With the Xpert Bladder Cancer Monitor Assay (ANTICIPATE X)
Not yet recruiting NCT05962541 - Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic Trans-urethral Resection of Bladder Tumours (PDD-TURBT) to Avoid Secondary Resections (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs) Phase 4
Active, not recruiting NCT05864599 - External Validation of Uromonitor as a Biomarker for Optimization of NMIBC Management by the CUETO Group
Not yet recruiting NCT03950362 - Bladder PREserVation by RadioTherapy and Immunotherapy in BCG Unresponsive Non-muscle Invasive Bladder Cancer Phase 2
Recruiting NCT05710848 - A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer Phase 1/Phase 2
Recruiting NCT05232136 - OH2 Oncolytic Viral Therapy in Non-Muscle-Invasive Bladder Cancer Phase 1/Phase 2
Recruiting NCT05825950 - Artificial Intelligence Prediction Tool in Non-muscle Invasive Bladder Cancer (NMIBC)
Recruiting NCT05626101 - Safety and Efficacy of Scheduled Intravesical Gemcitabine Versus Intravesical BCG for Intermediate and High Risk Non Muscle Invasive Bladder Cancer: A Prospective, Randomized Study N/A
Recruiting NCT05538663 - Intravesical BCG vs GEMDOCE in NMIBC Phase 3
Recruiting NCT06245759 - The Prognostic Impact of Tumor Location in Non-Muscle-Invasive Bladder Cancer Patients
Active, not recruiting NCT04690699 - LUMINOS-103: A Basket Trial Evaluating the Safety and Efficacy of Lerapolturev (PVSRIPO) and Lerapolturev in Combination With Anti-PD-1/L1 Checkpoint Inhibitors in Patients With Advanced Solid Tumors Phase 1/Phase 2
Completed NCT05675176 - Antegrade Observational Comparative Study for the Intravesical Instillation Therapy of Bacillus Calmette Guerin With the Use of Different Types of Urinary Catheters in Patients With Urinary Bladder Cancer